Skip to main content
main-content

30-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Introducing a phase 1 trial of ladiratuzumab vedotin

Jame Abraham describes the design of a phase 1 trial now investigating the novel LIV-1-targeted antibody–drug ladiratuzumab vedotin in patients with metastatic breast cancer (3:43).

Read transcript

Related content

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The HER2CLIMB trial

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The KEYNOTE-355 trial

Have your say on Medicine Matters

Visit the conference hub

Image Credits